Blacksmith Medicines, Inc. (Blacksmith), a company develops medicines targeting metal-dependent enzymes, and Forge Therapeutics (Forge), announce that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.
